|
 |
imatinib mesylateThis page contains recent news articles, when available, and an overview of imatinib mesylate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.We have previously shown that small molecule PDGF receptor tyrosine kinase inhibitors (RTKI) can drastically attenuate radiation-induced pulmonary fibrosis ... 7thSpace Interactive (press release) ChemGenex seals licensing deal with Hospira - Dec 13, 2009 ...leukaemia (CML) who have failed to respond to current traditional treatments, imatinib mesylate, and who also have a particular leukaemia mutation. ... Sydney Morning Herald Bone Drugs Linked to Fewer Cases of Breast Cancer - Dec 15, 2009 Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic ... NCI Cancer Bulletin EpiCept Provides Clinical and Business Update on Ceplene Program - Dec 15, 2009 ...in combination with Gleevec ® (imatinib mesylate) on the eradication of minimal residual disease (MRD) in adult patients with chronic myeloid leukemia. ... PharmaLive.com (press release) Kareem Abdul Jabbar likes his Chances with Leukemia - Nov 11, 2009 ...use Imatinib mesylate as first line therapy for CML (although Medpie.com staff could not find any mentioning of the survival rate of the control arm). ... Medpie.com (blog) Insulin-like growth factor binding protein-3 has dual effects on ... - Nov 10, 2009 Imatinib mesylate has significantly improved survival and quality of life of patients with gastrointestinal stromal tumors (GISTs). ... 7thSpace Interactive (press release) Imatinib Plus Chemo Improves Survival in High-Risk Leukemia Patients - Nov 10, 2009 Survival rates for children with a Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) more than double when imatinib mesylate was added ... American Journal of Hemotology and Oncology ACR: Gleevec Found Promising for Systemic Sclerosis Treatment results in ... - Oct 20, 2009 MONDAY, Oct. 19 (HealthDay News) -- In patients with systemic sclerosis, treatment with imatinib mesylate (Gleevec) may be a safe and effective therapy, ... ModernMedicine Rapamune™ May Improve Responses to Gleevec® in Patients with Chordoma - Nov 4, 2009 Annals of Oncology. 2009;20:1886-1894. [2] Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer. 2004;101:2086-2097. Cancer Consultants Research and Markets: Competitor Analysis: PDGF-R Agonists and Antagonists - a ... - Oct 19, 2009 Key Topics Covered: * PDGF-R Agonists * Biologics as PDGF /-R Antagonists * Imatinib Mesylate Pipeline * Multi-Target PDGF Receptor Antagonists * Dual PDGF ... Reuters Priority status granted to ChemGenex's leukaemia treatment - Nov 9, 2009 Omapro (omacetaxine mepesuccinate), is a treatment for individuals with CML who have failed treatment with the imatinib mesylate, which is known as Glivec ... Australian Life Scientist Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against ... - Oct 19, 2009 About Gleevec (11) Gleevec® (imatinib mesylate) tablets are indicated for the treatment of newly diagnosed adult patients with Philadelphia ... Reuters Europe May See 10 New Orphan Products a Year - Nov 6, 2009 Current costs to national healthcare systems primarily come from two product families: Novartis's Gleevec (imatinib mesylate) and enzyme replacement therapy ... Pharmaceutical Technology Magazine Mesothelioma program at University of Texas cancer center sees 150 new ... - Oct 25, 2009 His cancer was stabilized in August 2008 after receiving radiation therapy and participating in a clinical trial for Gleevec (imatinib mesylate), ... Mesothelioma News עמותת חולי סרטן הגיסט - "תנו לנו להמשיך לחיות" - Oct 21, 2009 Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. ... סקופ Imatinib mesylate is effective in children with chronic myelogenous … - Dec 8, 2005 Preliminary data were presented at the 45th annual meeting of the American Society of Hematology, San Diego, CA, December 6–9, 2003. ... Nature.com imatinib mesylate - Nov 26, 2008 Treatment with imatinib is expected to continue for life to keep the cancer from coming back. 2 A study suggests that over 80% of people with CML who keep ... WebMD Imatinib mesylate versus allogeneic BMT for patients with chronic... - Aug 4, 2008 Correspondence: Professor H Bittencourt, Hematology and Stem Cell Transplantation Service, Hospital das Clinicas da Universidade Federal de Minas Gerais, ... Nature.com Imatinib mesylate for refractory acute myeloblastic leukemia harboring... - Jul 28, 2005 Correspondence: Dr N Asou, Department of Hematology, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan. Fax: +81 96 363 5265; ... Nature.com High-dose imatinib mesylate combined with vincristine and … - Jan 26, 2006 Correspondence: Dr P Rousselot, Service d'Hématologie et d'Oncologie, Hôpital Mignot, 177, rue de Versailles, 78157 Le Chesnay, France. ... Nature.com HC suspends hearings in Novartis' Glivec case - Aug 10, 2007 However, the invention of Glivec's base compound, Imatinib mesylate, was patented in 1993, and is therefore not eligible for a patent in India, which joined ... Economic Times Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life... - Oct 8, 2008 EAST HANOVER, NJ, Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the ... RedOrbit Natco challenges Novartis' patent on anti-cancer drug - Jun 21, 2005 NATCO Pharma Ltd (NPL) has filed an opposition to the patent claim made by Novartis India Ltd for an anti-cancer drug (Imatinib Mesylate) with the ... Hindu Business Line … reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib... - Jan 1, 2007 Jefferson Medical College, Center for Translational Medicine, 1025 Walnut St., College Bldg., Room 316, Philadelphia, Pennsylvania 19107, USA. e-mail: ... Nature.com Cardiotoxicity of the cancer therapeutic agent imatinib mesylate - Jul 23, 2006 Ultrastructural analysis and assay for mitochondrial permeability transition pore opening. (a) Electron micrographs of hearts from mice treated with ... Nature.com Cardiotoxicity of the cancer therapeutic agent imatinib mesylate - Jul 23, 2006 ...(a,b) Cytosolic vacuolization and lipid droplet accumulation. NRVMs were treated with vehicle or imatinib (5 M) for the durations shown and were then ... Nature.com HC to hear Novartis case on October 8 - Sep 11, 2007 However, the invention of Glivec's base compound, Imatinib mesylate, was patented in 1993, and is therefore not eligible for a patent in India, which joined ... Economic Times FDA Approves Imatinib Mesylate to Prevent Recurrence of GI Stromal … - Dec 22, 2008 ROCKVILLE, Md -- December 22, 2008 -- The US Food and Drug Administration (FDA) has approved a new indication for imatinib mesylate (Gleevec) to prevent ... DG News … 13 - Sunitinib prolongs survival in GIST patients after imatinib... - Nov 3, 2005 Failure of imatinib mesylate therapy was either the result of resistance or intolerance. Sunitinib treatment was in a repeated 6-week cycle consisting of a ... eurekalert.org Cardiotoxicity of the cancer therapeutic agent imatinib mesylate - Jul 23, 2006 ...(a) Imatinib activates the ER stress response in vivo and in vitro. Top left, immunoblot of lysates of hearts from two vehicle-treated and two ... Nature.com … and nonhematological toxicities of imatinib mesylate in patients... - Jul 1, 2007 Conclusion : Imatinib mesylate is a well-tolerated drug with some adverse events that are only ... Before starting imatinib mesylate, complete blood count, ... Free with registration - Indian Journal of Pharmacology - AccessMyLibrary.com … reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib... - Aug 1, 2006 Global Medical Affairs, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, New Jersey 07936, USA. e-mail: Samantha_jane.owen@novartis.com ... Nature.com … with a poor prognosis in imatinib mesylate-resistant chronic... - Nov 10, 2005 Correspondence: Dr T Leguay, Service des Maladies du Sang, Hôpital du Haut-Lévèque, 33600 Pessac, France. Fax: +33 5 57 65 65 14; ... Nature.com Novartis faces fresh patent fight in India - Jan 10, 2008 Novartis' patent filing in the Chennai patent office, for an alfa crystal form, or another modified form of its cancer drug imatinib mesylate, has come to ... Livemint Cardiotoxicity of the cancer therapeutic agent imatinib mesylate - Jul 23, 2006 2 The Molecular Cardiology Research Institute, Tufts–New England Medical Center and Tufts University School of Medicine, 750 Washington Street, Boston, ... Nature.com Glivec patent appeal's pending - Aug 7, 2007 The invention of Glivec's base compound — Imatinib mesylate — was patented in 1993, and is therefore not eligible for a patent in India, which joined WTO ... Economic Times … Release: Early Data Show Potential for Imatinib Mesylate Tablets... - Oct 8, 2008 Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Platelet-derived growth factor receptor- in Gorham's disease - Dec 13, 2005 Imatinib mesylate was discontinued, and the patient's respiratory status improved ... A second trial of imatinib mesylate (200 mg/day) was commenced 4 weeks ... Nature.com … Part 2: a review of the cutaneous side effects of imatinib... - Mar 1, 2006 In the first part of this two part series on imatinib mesylate, ... (5-7) The diversity of cutaneous reactions to imatinib mesylate highlights tyrosine ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com Novartis: do Indian patent laws stifle research? - Aug 9, 2007 As soon as the law changed in India, Novartis preferred an application for beta crystalline form of imatinib mesylate (Gleevec) in 1998. ... Hindu Erythroid variant of chronic myelogenous leukemia - Nov 22, 2007 This patient was treated with imatinib mesylate and responded well. ... It was decided to initiate a trial of imatinib mesylate, although there was no known ... Nature.com India, Intellectual Property, Novartis Denied Patent for Gleevec -... - May 31, 2006 Thus imatinib mesylate is already known from prior publications. Also that imatinib mesylate normally exist in the beta crystals form which is ... Mondaq News Alerts - Mondaq News Alerts (Registration) Management of chronic myeloid leukaemia in relapse following donor … - Oct 10, 2005 Further DLI was used in the treatment of 11 patients, imatinib mesylate in ... One patient in molecular relapse was treated with imatinib mesylate alone. ... Nature.com Imatinib mesylate and docetaxel: minimal response in platinum... - Aug 14, 2008 A combination of imatinib mesylate and docetaxel produced only a modest response in patients with recurrent, platinum-resistant or refractory ovarian cancer ... HemOncToday Drug major moves court - Jan 30, 2007 ...of its patent application for beta crystalline form of imatinib mesylate, ... form of imatinib mesylate, sold under the brand name Gleevec/Glivec. ... Hindu Exclusive marketing rights for Novartis' cancer drug cancelled - Feb 22, 2006 Interestingly, on January 25 this year, the Swiss company had lost a patent claim for the anti-cancer drug — Imatinib Mesylate — before the office of the ... Hindu Business Line Identification of a rare e8a2 BCR-ABL fusion gene in three novel... - Oct 13, 2005 The introduction of imatinib mesylate therapy at 400 mg/day allowed complete hematologic and cytogenetic responses at 6 months and a major molecular ... Nature.com Reducing uncertainty in health-care resource allocation - Feb 26, 2007 Imatinib mesylate reduces GIST cell proliferation by binding to the catalytic ... The calculations reveal that treatment with imatinib mesylate results in ... Nature.com … Endorsed Important Safety Information on Gleevec (Imatinib... - Oct 2, 2006 Gleevec* (imatinib mesylate) is used to treat adult patients who have a specific type of blood cancer called Chronic Myeloid Leukemia (CML) and a specific ... DG News Chronic Myeloproliferative Disorders Treatment (PDQ®) - May 8, 2008 5,6] Case reports suggest symptomatic responses to imatinib mesylate for patients with ... 6,7,8][Level of evidence: 3iiiDiv] Imatinib mesylate acts as an ... WebMD MNCs told to supply `patented' anti-cancer drug - Jan 21, 2005 No patent for `Imatinib Mesylate' was ever filed in India, and, therefore, there was no question of the plaintiffs being entitled to any protection on the ... Hindu Business Line `Efficacy' factor will be key to Glivec patent case - Jun 22, 2007 Imatinib mesylate is used in the marketed formulation of Novartis blockbuster anticancer drug Glivec. The "patentability" will depend on whether the IPAB is ... Hindu Business Line … Long-Lasting Responses in Imatinib Mesylate-Resistant GI Stromal … - Feb 2, 2006 ..."While first-line therapy for GIST is imatinib mesylate, secondary resistance usually develops after a year or two in patients who initially respond to the ... DG News Progressive arm and leg stiffness in a patient with chronic renal … - Feb 5, 2008 The tyrosine kinase inhibitor imatinib mesylate blocks the signaling pathway ... 17, 20, 21 A pilot study of daily 400 mg imatinib mesylate in two patients ... Nature.com … Plus Iressa (Gefitinib) or Gleevec (imatinib mesylate) in Metastati... - Nov 22, 2005 PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa (gefitinib) in ... DG News Should adjuvant imatinib be used as primary treatment for gastrointest... - Oct 5, 2007 Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients ... (2005) Adjuvant imatinib mesylate in patients with primary high risk ... Nature.com Milestone 24 : Nature Milestones in Cancer - Apr 1, 2006 Imatinib mesylate was rationally designed to block the BCR–ABL active site, ... Yet, it turns out that imatinib mesylate is not as selective as first ... Nature.com … mediates anti-neoplastic effects of Imatinib mesylate (Glivec) in... - Oct 25, 2005 However, it is unclear whether the selective tyrosine kinase (TK) inhibitor, imatinib mesylate, is linked to the Wnt/-catenin cascade and is able to ... Journal of Clinical Endocrinology and... St. John's wort and imatinib mesylate.(Drug-Drug Interactions) - Jan 1, 2005 It is not uncommon for patients with cancer to receive treatment for their depressive symptoms. In addition to prescription antidepressants, ... Free with registration - Brown University Psychopharmacology... - AccessMyLibrary.com Patent trouble - Feb 10, 2007 They also argued that Novartis failed to show that imatinib mesylate differed significantly from other forms of imatinib and questioned the independence of ... The Hindu Patents panel wants Novartis documents on efficacy claims - Nov 19, 2008 Glivec, a modified form of a drug known as imatinib mesylate, and invented before 1995, had been granted patents in several countries, including Switzerland ... Livemint … With 800 mg/day Imatinib Mesylate Significantly Improved Progressio... - May 15, 2006 Gleevec (imatinib mesylate) tablets are indicated for the treatment of patients with KIT (CD117)-positive unresectable and/or metastatic malignant GIST. ... DG News … in the BCR-ABL kinase domain modifies sensitivity to imatinib... - Jun 23, 2005 Imatinib mesylate (Glivec, STI571) inhibits BCR-ABL TK activity and induces ... Several Bcr-Abl kinase domain mutants associated with imatinib mesylate ... Nature.com Chronic Myelogenous Leukemia Treatment New Strategy - Jan 18, 2007 Imatinib mesylate (Gleevec) is a highly effective anti-cancer agent that has revolutionized the course of therapy for patients with chronic myelogenous ... emaxhealth.com Combination Of Two Novel Anti-cancer Agents May Help Fight CML … - Jun 1, 2008 Imatinib mesylate, or Gleevec, is a highly effective anti-cancer agent that has revolutionized the course of therapy for patients with CML. ... sciencedaily.com Drug Safety; Imatinib mesylate effective in CML in late chronic and … - Mar 7, 2006 2006 MAR 7 - (NewsRx.com) -- Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and after stem ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Expanding the therapeutic arsenal.(Leukemia) | Article from Science … - Jan 1, 2005 The spinal drip was necessary because imatinib mesylate doesn't pass ... The success of imatinib mesylate "inspired a lot of people to take an active ... Pay-Per-View - Science News - HighBeam Research Gastrointestinal Stromal Tumors - Mar 26, 2008 Ongoing studies are testing to see if imatinib mesylate can delay or ... The role of imatinib mesylate in pediatric GIST is being studied at this time. ... WebMD Researchers Develop New Strategy For The Treatment Of CML - Jan 22, 2007 Imatinib mesylate (Gleevec) is a highly effective anti-cancer agent that has revolutionized the course of therapy for patients with CML. ... Medical News Today - Medical News Today (press release) … troubles for cancer wonder drug.(Side effects of Glivec (Imatinib... - Aug 7, 2006 Glivec (Imatinib mesylate), the first targeted cancer therapy, could cause heart failure. And this unanticipated side effect that could have implications ... Free with registration - Chemistry and Industry - AccessMyLibrary.com Cancer Vaccine; Imatinib mesylate overcomes tumor-induced CD4+ T- … - Apr 4, 2005 2005 APR 4 - (NewsRx.com) -- Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones CD34+/Ph+ cells are still detectable in chronic myeloid leukemia... - Aug 9, 2007 Imatinib mesylate induces complete cytogenetic response (CCR) in more than 85% of ... Imatinib mesylate discontinuation in patients with chronic myelogenous ... Nature.com Leukemia - BCR-ABL activity and its response to drugs can be … - Mar 30, 2006 Imatinib mesylate (IM) was a gift from Novartis Pharma (Basle, Switzerland). ... Effect of increasing concentrations of imatinib mesylate (IM) on K562 and ... Nature.com Sprycel(TM) (Dasatinib) Approved in Europe -- The First Significant … - Nov 22, 2006 When this happens, imatinib mesylate, the current standard treatment, may be unable to block its activity. Sprycel is an oral, multi-targeted therapy that ... DG News Novartis loses patent claim on cancer drug — Patents Controller... - Jan 26, 2006 IN a major setback, the Swiss pharmaceutical giant Novartis AG has lost a patent claim for an anti-cancer drug — Imatinib Mesylate — before the office of ... Hindu Business Line Leukemia; Research in leukemia provides new insights - Mar 28, 2006 According to a study from Japan, "Imatinib mesylate is a specific inhibitor of BCR-ABL tyrosine kinase, which is now widely used for the treatment of CML ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Cancer Therapy; Use of imatinib mesylate in malignant mesothelioma … - Dec 13, 2005 According to a study from the Netherlands, "Twenty-five patients with histologically proven malignant mesothelioma participated in a trial of imatinib ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Chronic Myeloid Leukemia; Imatinib mesylate treatment induced... - Jan 3, 2006 2006 JAN 3 - (NewsRx.com) -- Imatinib mesylate (IM) treatment induced pityriasis rosea (PIZ)-like eruptions in patients with chronic myeloid leukemia (CML). ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Testicular Cancer; Imatinib mesylate stops malignant Leydig cell... - Apr 25, 2005 2005 APR 25 - (NewsRx.com) -- Imatinib mesylate stops malignant Leydig cell tumor ... "We therefore evaluated the effects of imatinib mesylate (imatinib), ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones In the interest of patients - Mar 24, 2007 Under this interim system, Novartis submitted a so-called black box application to register the beta crystal form of imatinib mesylate. ... The Hindu … a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate... - Nov 23, 2006 Imatinib mesylate treatment (400 mg/day) was commenced in November 2005 and continued for 3 ... Response to imatinib mesylate in patients with chronic ... Nature.com Absolute quantitative detection of ABL tyrosine kinase domain point … - Jul 10, 2008 Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French ... Nature.com Evidence for the interaction of imatinib at the transport-substrate... - Aug 9, 2007 Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses ... Imatinib mesylate (STI571) is a substrate for the breast cancer ... Nature.com Broad molecular screening of an unclassifiable myeloproliferative … - Mar 24, 2005 Targeted therapies using all-trans-retinoic acid in acute promyelocytic leukemias or the tyrosine kinase inhibitor Imatinib Mesylate in CML have ... Nature.com Testicular Cancer; Imatinib mesylate stops malignant Leydig cell... - Apr 25, 2005 ..."Leydig cell tumors are usually benign tumors of the male gonad. However, if the tumor is malignant, no effective treatments are currently available. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones … drug.(Side effects of Glivec (Imatinib mesylate)) | Article from... - Aug 7, 2006 Side effects of Glivec (Imatinib mesylate)) ... find Chemistry and Industry articles. Glivec (Imatinib mesylate), the first targeted cancer therapy, ... Pay-Per-View - Chemistry and Industry - HighBeam Research Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with … - Aug 9, 2007 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia ... Nature.com New treatment hope for systemic sclerosis - Dec 28, 2006 Similarly, imatinib mesylate effectively suppressed the development of fibrosis ... However, more extensive animal studies of imatinib mesylate, as well as ... eurekalert.org HC rejects petition by Novartis - Aug 6, 2007 The appeal challenged rejection of its patent application for beta crystalline form of imatinib mesylate, sold under the brandname Gleevee/Glivec. ... Free with registration - PTI - The Press Trust of India Ltd - AccessMyLibrary.com New Treatment Hope For Systemic Sclerosis - Jan 3, 2007 Similarly, imatinib mesylate effectively suppressed the development of fibrosis ... However, more extensive animal studies of imatinib mesylate, as well as ... Medical News Today - Medical News Today (press release) Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype - Nov 30, 2006 Approval summary for imatinib mesylate capsules in the treatment of chronic ... Metabolism and disposition of imatinib mesylate in healthy volunteers. ... Nature.com … of the cancer therapeutic agent imatinib mesylate | www.nature.com - Jul 26, 2006 In vitro data, plus 10 patients are presented with congestive failure while on Gleevec. BUT, of the 10 patients, 7 were on doses that exceeded the standard ... Gerson Lehrman Group Imatinib mesylate minimally affects bcr-abl+ and normal monocyte- … - Feb 3, 2006 1 Correspondence: Unité de Thérapie Cellulaire et Clinique Transfusionnelle, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010 Paris, France. ... Journal of Leukocyte Biology (subscripti... Glivec - Imatinib mesylate - Medical Drug - Sep 11, 2007 Glivec works by interfering effects of a tumour protein called tyrosine kinase which constantly induces the production of abnormal white blood cells in ... Virtual Medical Centre - The Virtual Medical Centre Leukemia; Reports from the United States, Japan and Scotland add new ... - Jun 12, 2006 According to a study from Japan, "Imatinib mesylate is a specific inhibitor of BCR-ABL tyrosine kinase, which is now widely used for the treatment of CML ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones Pfizer's Sutent Receives Positive Opinion in the European Union For... - Apr 28, 2006 GIST patients with advanced disease after surgery are treated with imatinib mesylate, where patients with mRCC are generally treated with cytokines. ... Free with registration - PR Newswire - AccessMyLibrary.com The Glivec case - Mar 12, 2005 They argued that no patent was filed in India for imatinib mesylate. Novartis said that the EMR was conferred for a period of five years, or until an order ... The Hindu Natco opposes Novartis patent claim - Jun 20, 2005 Novartis had earlier obtained exclusive marketing rights for 'Imatinib Mesylate', a drug useful in the treatment of certain forms of chronic myeloid ... Rediff Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an … - Sep 8, 2005 ...(HU: hydroxyurea, IM: imatinib mesylate, Bus: busulphan, IFN: interferon, ... Several Bcr-Abl kinase domain mutants associated with imatinib mesylate ... Nature.com Selection patent and its discontents - Aug 22, 2007 The 1 993 US patent of imatinib disclosed the salt imatinib mesylate. To circumvent the problem of earlier disclosure, Novartis claimed its 1998 Indian ... Hindu Business Line Leukemia - BCR-ABLT315I transcript disappearance in an imatinib- … - May 31, 2007 The Abl tyrosine kinase inhibitor imatinib mesylate (IM) now represents the new ... Mutation status and clinical outcome of 89 imatinib mesylate-resistant ... Nature.com Patients Receiving Adjuvant Imatinib for GISTs Show 97% Survival at 3... - Jan 26, 2008 ...[Presentation title: Efficacy of Adjuvant Imatinib Mesylate Following Complete Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST) at High ... DG News Can application of serine protease inhibitors TPCK and TLCK provide … - Jan 10, 2005 5 Authors concluded that imatinib mesylate induced a caspase-independent, necrosis-like ... A novel mechanism for imatinib mesylate-induced cell death of ... Nature.com New Treatment Hope for Systemic Sclerosis - Jan 22, 2007 Similarly, imatinib mesylate effectively suppressed the development of fibrosis in the infected mice. These results were achieved by induction of the ... Medscape Intensive chemotherapy and autologous hematopoietic stem cell … - Mar 9, 2006 Imatinib mesylate, the most active monotherapy for CML in all phases of the disease, results in a median survival of patients with blastic phase CML of 6.9 ... Nature.com … in patients treated with interferon followed by imatinib mesylate... - Jul 14, 2005 Imatinib mesylate has been shown to selectively inhibit the tyrosine ... Guilhot F. Indications for imatinib mesylate therapy and clinical management. ... Nature.com A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia ... - Jun 22, 2006 2 Therapy with imatinib mesylate (Gleevec) renders sustained hematologic ... Therapy with the tyrosine kinase inhibitors imatinib mesylate and AMN107 was ... Nature.com IPAB Bench rejects Novartis plea - Jul 21, 2007 The appeal challenged the rejection of its patent application for beta crystalline form of imatinib mesylate, sold under the brandname Gleevee/Glivec. ... Hindu Same Protein Linked to Both Immune Activation and Response to Anti- … - Mar 2, 2005 Imatinib mesylate inhibits ABL's activity in leukemia cells and, ... While imatinib mesylate targets and inhibits the activity of ABL proteins in cancer ... emaxhealth.com Mutations of the BCR-ABL-kinase domain occur in a minority of... - Jan 25, 2007 Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases ... Nature.com Mathematical models of targeted cancer therapy - Oct 10, 2006 Before the introduction of imatinib mesylate (Glivec) as a targeted therapy for CML, treatment options were relatively unsuccessful and often costly or of ... Nature.com Press Release: Novartis completes submissions in US and Europe for … - Apr 10, 2006 About Gleevec Tablets Gleevec (imatinib mesylate) tablets are indicated for . ... The FDA has approved imatinib mesylate (Gleevec) tablets for the treatment ... Pay-Per-View - PR Newswire - HighBeam Research Conor Medsystems Signs Multi-Drug Agreement to Develop Next- … - Mar 15, 2005 Imatinib mesylate belongs to a class of drugs collectively known as signal transduction inhibitors. It is an inhibitor of several protein-tyrosine kinases ... Angioplasty.Org Heart warning coming for Gleevec.(LATEBREAKERS)(Brief article) - Oct 23, 2006 Imatinib mesylate is approved for the treatment of chronic myeloid leukemia and metastatic malignant gastrointestinal stromal tumors. Free with registration - Drug Topics - AccessMyLibrary.com Molecular characterization of the idiopathic hypereosinophilic... - Mar 17, 2005 Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003; 101: 4714−4716. | Article | PubMed | ChemPort | ... Nature.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |